Stock OCS OCULIS HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Company Oculis Holding AG

Equities

OCS

CH1242303498

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
 23:00:00 27/05/2024 BST 		5-day change 1st Jan Change
11.9 USD +0.42% Intraday chart for Oculis Holding AG 0.00% +5.97%
05-08 Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-24 H.C. Wainwright Adjusts Price Target on Oculis Holding to $28 From $29, Keeps Buy Rating MT

Business Summary

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

Number of employees: 36

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Products and Substances
100.0 %
- - 1 100.0 % -

Managers

Managers TitleAgeSince
Riad Sherif CEO
 Chief Executive Officer 56 30/11/17
Sylvia Cheung DFI
 Director of Finance/CFO 50 31/08/20
Ramin Tadayoni CTO
 Chief Tech/Sci/R&D Officer 54 02-27
Rebecca Weil PRN
 Corporate Officer/Principal - 10/09/23
Bastian Dehmel PRN
 Corporate Officer/Principal 54 31/12/21
Páll Jóhannesson PRN
 Corporate Officer/Principal 44 -
Virginia R. Dean HRO
 Human Resources Officer 58 02-27

Members of the board

Members of the board TitleAgeSince
Anthony Adam Rosenberg CHM
 Chairman 71 31/03/18
Martijn Kleijwegt BRD
 Director/Board Member 69 02/03/23
Geraldine O'Keeffe BRD
 Director/Board Member 58 02/03/23
Lionel Carnot BRD
 Director/Board Member 56 30/11/17
Christina Ackermann BRD
 Director/Board Member 59 02/03/23
Pravin Dugel BRD
 Director/Board Member 60 31/03/20
Riad Sherif CEO
 Chief Executive Officer 56 30/11/17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 46,443,700 43,427,273 ( 93.51 %) 0 93.51 %

Shareholders

NameEquities%Valuation
LSP Management Group BV
14.54 %
5,327,362 14.54 % 64 M $
Brunnur Ventures GP ehf
6.373 %
2,335,841 6.373 % 28 M $
Shanghai Bioveda Investment Management Consulting Co. Ltd.
5.648 %
2,070,020 5.648 % 25 M $
Pivotal Bioventure Partners Investment Advisor LLC
5.545 %
2,032,296 5.545 % 24 M $
Martijn Kleijwegt
5.450 %
1,997,302 5.450 % 24 M $
NOVARTIS AG
4.675 %
1,713,521 4.675 % 20 M $
abrdn, Inc.
3.351 %
1,228,042 3.351 % 15 M $
Riad Sherif
2.397 %
878,486 2.397 % 10 M $
Páll Jóhannesson
0.6800 %
249,224 0.6800 % 3 M $
Anthony Adam Rosenberg
0.2638 %
96,670 0.2638 % 1 M $
NameEquities%Valuation
Tyrus Capital S.A.M.
-
133,332 - 257 331 $
MMCAP International Inc. SPC
-
73,525 - 141 903 $
Greenland Capital Management LP
-
50,100 - 96 693 $
Jane Street Group LLC
-
45,703 - 88 207 $
Gabelli & Company Investment Advisers, Inc.
-
42,642 - 82 299 $
Moore Capital Management LP
-
41,666 - 80 415 $
D.E. Shaw & Co., Inc.
-
37,216 - 71 827 $
Walleye Capital LLC
-
33,899 - 65 425 $
Calamos Advisors LLC
-
33,333 - 64 333 $
Tenor Capital Management Co. LP
-
33,333 - 64 333 $

Company contact information

Oculis Holding AG

Bahnhofstrasse 7

6300, Zug

+41 41 711 9325

http://oculis.com
address Oculis Holding AG(OCS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Oculis Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.89 CHF
Average target price
25.74 CHF
Spread / Average Target
+136.37%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
OCULIS HOLDING AG Stock Oculis Holding AG
+5.97% 498M
MODERNA, INC. Stock Moderna, Inc.
+48.67% 56.69B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.76% 41B
LONZA GROUP AG Stock Lonza Group AG
+37.86% 38.11B
CELLTRION, INC. Stock Celltrion, Inc.
-11.22% 26.89B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.25% 25.59B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.10% 18.59B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+1.88% 12.39B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.43% 11.99B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+21.74% 11.88B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. OCS Stock
  4. Company Oculis Holding AG